About CLS Investment Criteria Our Team Scientific Advisors Portfolio News Contact
 
 
 

 

Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE™ Bioresorbable Scaffold
October 28, 2013


KFx Medical Corporation Receives $29 Million Award and a Finding of Willful Infringement by Arthrex Inc. in Patent Infringement Case
October 9, 2013


Amaranth Medical Raises $20 Million in Series B to Support Development of the FORTITUDE™ Bioresorbable Scaffold
October 7, 2013


KFx Medical Corporation Announces License of Its Knotless Double Row Patents
August 15, 2013


EnteroMedics Submits PMA Application for FDA Approval of VBLOC Therapy in Obesity
June 25, 2013


Mirabilis Medica, Woman's Healthcare Company, Announces Initial Closing In Financing Of Up To $13 Million Led By GSR Ventures
June 17, 2013


Insiders, New Investors to Join $25M Series B Round for Amaranth Medical
June 13, 2013


KFx Medical Corporation announces allowance from United States Patent Office of two additional orthopedic surgical patents
May 22, 2013


Takeda to Acquire Inviragen, Inc. - Obtains Promising Vaccine Candidates Against Dengue and Hand, Foot and Mouth Disease, Advancing Takeda's Commitment to Vaccines and Global Health
May 7, 2013


Inviragen Advances DENVax into Second Stage of Ongoing Phase 2 Clinical Study
February 27, 2013


VABIOTECH Licenses Cell-Based Japanese Encephalitis Technology from Inviragen
January 3, 2013


Inviragen and the International Vaccine Institute Expand Partnership - Studies will Examine Dengue Impact in Asia and Latin America
November 8, 2012


EnteroMedics Announces EMPOWER Trial Hypertension Data Presented at the American Heart Association's 2012 Scientific Sessions
November 7, 2012


Health Fidelity and Intelligent Medical Objects (IMO) Sign Multi-Year Agreement to Leverage Clinical Expertise and Solutions
October 31, 2012


Health Fidelity Releases REVEAL Version 2.0
September 25, 2012


Integrated Document Solutions Selects Health Fidelity's REVEAL™ to Improve Hospital Systems Revenue Cycle Management
August 9, 2012


AXIOS™ Stent and Delivery System CE Mark Approval Expanded to Include Biliary Tract Drainage - Offers New Endoscopic Options for Treating the Gallbladder and Bile Duct
July 17, 2012


Great Lakes Pharmaceuticals, Inc. announced today the initiation of the clinical study of the first Company product, the antimicrobial lock solution, B-Lock™
July 12, 2012


Health Fidelity REVEAL v1.1 Extracts Unstructured Clinical Data
July 12, 2012


ZyDoc Selects Health Fidelity’s REVEAL™ NLP Platform to Accelerate Time to Value for its MediSapien Web Services
June 12, 2012


EnteroMedics Announces First Commercial Implants of the Maestro(R) Rechargeable System
June 5, 2012


EnteroMedics Added to Russell 3000(R) and Russell 2000(R) Indexes
June 5, 2012


Health Fidelity REVEAL Helps Drive Quality Improvement, Care Efficiency and Information Exchange
April 26, 2012


EnteroMedics Announces First Commercial Shipment of the Maestro(R) Rechargeable System to Australia
April 3, 2012


EnteroMedics Announces 2.5-Year Diabetes, Hypertension and Weight Loss Data From the Maestro(R) RC System DM2 ENABLE Study
April 3, 2012


INVIRAGEN HAND, FOOT AND MOUTH DISEASE VACCINE GENERATES IMMUNE RESPONSES IN 100% OF STUDY PARTICIPANTS
March 12, 2012


BayScribe Selects Health Fidelity's NLP Platform
March 6, 2012


U.S. Study Says Eye Care Professionals Would Switch 36% Of Their Presbyopic Patients Using Eyeglasses To A New Easy-To-Fit Contact Lens Design For Presbyopia
Feburary 28, 2012


Program from Health Fidelity accelerates integration of clinical natural language processing (NLP), bolstering the HIT ecosystem
Feburary 20, 2012


Columbia Grants Health Fidelity Exclusive License to MedLEE NLP
January 11, 2012


EnteroMedics Announces Completion of Patient Enrollment and Device Implantation in the ReCharge Pivotal Trial for Obesity
December 28, 2011


EnteroMedics Receives First Approval for the Active Implantable Medical Device Components of the Maestro System From Australian Therapeutic Goods Administration (TGA)
December 13, 2011


Inviragen Presents Safety and Immune Response Data from a Phase 1 Study of its Two-Dose Dengue Vaccine, DENVax
December 7, 2011


EnteroMedics Announces Updated Data From VBLOC DM2 ENABLE Study and Caloric Intake Study Results to Be Presented at the 29th Annual Obesity Society Meeting
October 3, 2011


EnteroMedics Announces Presentation of Maestro(R) RC System Clinical Data at the XVI World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
September 2, 2011


Inviragen and University of Texas Medical Branch Receive Funding for Development of a Novel Recombinant Chikungunya Virus Vaccine
August 15, 2011


San Diego's KFx Medical Corporation Files Patent Infringement Suit Against Arthrex
August 2, 2011


International Vaccine Institute and Inviragen Announce a Collaboration to Accelerate Development of a Dengue Vaccine
August 2, 2011


Minimally Invasive Devices, Inc. Awarded CE Mark for FloShield
July 20, 2011


Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore
June 15, 2011


EnteroMedics Announces Maestro® RC System Updated Weight Loss Data to Be Presented at the American Society for Metabolic and Bariatric Surgery Annual Meeting
June 14, 2011


EnteroMedics Announces First Implant in ReCharge Pivotal Trial for Obesity
May 18, 2011


Xlumena, Inc. Closes $7M Series B Venture Financing Round
April 28, 2011


EnteroMedics Receives CE Mark Certification for the Maestro RC System, Allowing Australian Regulatory Application to Move Forward
March 28, 2011


Inviragen and Duke-NUS Form Collaborative Vaccine Research and Development Program
January 26, 2011


EnteroMedics Announces Data From Australian Patient Cohort in EMPOWER Study and From Caloric Intake Study
November 8, 2010


Novel Recombinant Chikungunya Virus Vaccine Shown to be Safe and Effective in Multiple Animal Models
November 4, 2010


Inviragen Receives Two Therapeutic Discovery Project Grants for Vaccine Development
November 2, 2010


Inviragen Initiates DENVax Phase 1 Clinical Testing in Colombia
October 25, 2010


EnteroMedics Announces Updated Data from VBLOC-DM2, EMPOWER and VBLOC RF2 Studies
October 20, 2010


Inviragen and PharmaJet Receive $15.5 Million NIAID Contract to Develop a Needle-free Dengue Vaccine
October 12, 2010


EnteroMedics Completes $6.3 Million Convertible Preferred Stock Offering
September 30, 2010


EnteroMedics Achieves Major Milestones in Global Regulatory and Commercialization Strategy for the Maestro System
August 2, 2010


KFx Medical Corporation Announced Today It Has Received FDA 510k Clearance for Product(s) Used in a Wide Variety of Arthroscopic Tenodesis Knee Procedures Such as: ACL, PCL, and Patellofemoral Ligament (MPFL) Reconstruction
May 25, 2010


Inviragen’s Dengue Vaccine to Begin Clinical Testing
May 19, 2010


Inviragen Merger Profiled in Inc. Magazine
May 7, 2010


FDA Clears Xlumena’s NAVIX™ Access Device
April 28, 2010


EnteroMedics Extends Neuroblocking Technology Research and Development Collaboration
March 17, 2010


EnteroMedics Announces Regulatory Path Forward Following FDA Meeting
March 15, 2010


EnteroMedics Announces Regulatory Path Forward Following FDA Meeting
January 28, 2010


EnteroMedics Announces Weight Loss, Hypertension and Diabetes Data from EMPOWER and ENABLE Studies
Januray 14, 2010


EnteroMedics Announces Preliminary Results from Detailed Review of EMPOWER Study
November 12, 2009


Inviragen Merges with SingVax and Completes $15 million Series A Financing
October 6, 2009


KFx Medical Awarded Key Patent for Knotless Tissue Fixation and Double Row Rotator Cuff Surgery
September 9, 2009


Visioneering Technologies Raises $2.5M Series B
April 28, 2009


Visioneering Technologies Inc Raises $5 Million in Funding For New Presbyopia Solution
April 14, 2009


EnteroMedics Announces $15.89 Million Private Placement
February 20, 2009


EnteroMedics Announces Eighteen-Month Excess Weight Loss Results from its VBLOC-RF2 Feasibility Study
January 12, 2009


EnteroMedics Announces $20 Million Debt Financing
November 21, 2008


APT Pharmaceuticals Secures $32 Million in Series B Financing
September 30, 2008


EnteroMedics' Data from VBLOC-RF2 Feasibility Study and VBLOC-RC Study Presented Today at the American Society for Metabolic and Bariatric Surgery Meeting
June19, 2008


XLumena Spots $6M For Ultrasound Devices
June 4, 2008


Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids
APRIL 28, 2008


Astellas and CoMentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors
APRIL 25, 2008


EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients
February 26, 2008


KFx Medical Corporation Appoints Matt Meyer as its Vice President Marketing
February 20, 2008


EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy
January 8, 2008


EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity
January 7, 2008


CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy
January 7, 2008


APT Pharmaceuticals Expands Management Team
NOVEMBER 19, 2007


EnteroMedics Announces Initial Public Offering
NOVEMBER 14, 2007


APT Pharmaceuticals Closes New $22 Million Funding Round
OCTOBER 4, 2007


JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
SEPTEMBER 20, 2007


Mirabilis Closes $10.5 Million Series A Extension to Commercialize Non-invasive Treatment of Uterine Fibroids
AUGUST 21, 2007


KFx Medical Corporation Closes $10 Million Series B Financing
AUGUST 9, 2007


JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
JUNE 18, 2007


CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President
JUNE 6, 2007


APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection
JUNE 5, 2007


Enteromedics Files Registration Statement
for Proposed Initial Public Offering
MAY 25, 2007


CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
APRIL 10, 2007


Athenagen Announces Name Change to CoMentis
FEBRUARY 10, 2007


Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study
JANUARY 31, 2007


Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease
DECEMBER 13, 2006


Mirabilis Medica Names Mike Connolly CEO
OCTOBER 3, 2006


Athenagen Raises $50 Million in Series B Financing
SEPTEMBER 28, 2006


Amaranth Medical Closes $7.5 Million Series A Financing to Advance the Development of Bio-Absorbable Stents
SEPTEMBER 26, 2006


Mirabilis Raises $4 Million to Commercialize Non-Invasive Treatment of Uterine Fibroids
AUGUST 29, 2006


Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD
AUGUST 21, 2006


Athenagen Completes Merger with Zapaq
AUGUST 14, 2006


KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation
AUGUST 10, 2006


Athenagen Announces Publication of Results from a Proof-of-Concept Trial of its Novel alpha-7 Nicontinic Receptor Agonist in Schizophrenia
JUNE 15, 2006


Athenagen Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage Alzheimer's Drug Candidate to its Pipeline
APRIL 13, 2006


Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma
MARCH 23, 2006


Athenagen Adds A. Barr Dolan to its Board of Directors
FEBRUARY 22, 2006


Previous News Stories >

 
     
  About CLS  
 

 

CHARTER LIFE SCIENCES (“CLS”) is a clinical stage life sciences venture capital investor. CLS makes initial portfolio company investments in life sciences companies that are seeking capital to obtain initial clinical proof-of-efficacy of their products (see Investment Criteria), and we continue to support our successful portfolio companies with follow on investments until they are acquired or go public.

Our team is led by four Managing Partners who have worked together to create and build life sciences companies for over twenty years. We take a team approach to all of our investments, and our team brings extensive scientific, clinical, regulatory, operational and finance experience to each of our portfolio companies.

We play an active role in helping entrepreneurs build successful companies. Our time, energy and passion is devoted to investing in early stage life sciences opportunities. As a result, your company will be compared only against other early stage opportunities. So, at CLS, your preclinical biotech or medical device company will not be compared against a PIPE investment in an undervalued Phase III company. Early stage is what we do, and all we do.

We understand that early stage companies do not have all the answers and do not have all the data. We understand that many basic questions need investment capital to answer, and we understand that development plans and milestones are subject to lots of uncertainty and change. We understand what it takes to build a management team from scratch, and we invest in companies with little or no existing management. In short, we understand what it is to be an early stage entrepreneur, because each of us has been one.

Please look carefully at our investment criteria and our team, and if we are the type of partner that you would like to work with, please contact us.

 
     
   
 
 
© 2006 CHARTER LIFE SCIENCES